Latest Form 4 insider transactions

Shao-Lee Lin, Chief Executive Officer and a Director of Cue Biopharma, Inc., reported multiple transactions in common stock on June 1, 2026.

Joshua R. Disbrow, Chief Executive Officer and a Director of Aytu Biopharma, Inc, received 30,000 shares of common stock on July 28, 2026.

Greg Pyszczymuka, Chief Commercial Officer of Aytu Biopharma, Inc, received 20,000 shares of common stock on July 28, 2026.

Jarrett Disbrow, Chief Business Officer of Aytu Biopharma, Inc, received 15,000 shares of common stock on July 28, 2026.

Ryan J Selhorn, Chief Financial Officer of Aytu Biopharma, Inc, received 25,000 shares of common stock on July 28, 2026.

Equitable Holdings and Corebridge Financial announced that their respective stockholders have overwhelmingly approved the previously announced merger between the two companies.

Vivian H Liu, a Director of Aytu Biopharma, Inc, received 10,000 shares of common stock on July 28, 2026.

Abhinav Jain, a Director of Aytu Biopharma, Inc, received 10,000 shares of common stock on July 28, 2026.

Carl Dockery, a Director of Aytu Biopharma, Inc, received 10,000 shares of common stock on July 28, 2026.

John Donofrio Jr., a Director of Aytu Biopharma, Inc, received 10,000 shares of common stock on July 28, 2026.

Andrew C Richardson, a Director of Alpine Income Property Trust, Inc., sold 2,000 shares of common stock on July 28, 2026 for $20.28 per share.

Nicolas H Roelofs, a Director of Seer, Inc., reported multiple transactions in common stock on July 28, 2026.

Peter W Bell, a Director of Climb Global Solutions, Inc., received 5,855 shares of common stock on July 28, 2026.

Adrienne Uleau, CFO and VP of Amrep Corp., sold 4,000 shares of common stock on July 30, 2026 for $23.49 per share.

Osama M Musa, SVP and CTO of Ashland Inc., reported multiple transactions in common stock on July 29, 2026.

Darren S Raiguel, CHIEF OPERATING OFFICER of Eplus Inc, sold 2,000 shares of common stock on July 28, 2026.

NCS Multistage Holdings, Inc. announced its second quarter 2026 financial results, showing a 5% year-over-year revenue increase to $38.4 million, but a net loss of $4.6 million.

Barry Canton, a 10% owner of Ginkgo Bioworks Holdings, Inc., reported multiple transactions in common stock on July 28, 2026.

Vimal Kapur, Chief Executive Officer and a Director of Honeywell International Inc, reported multiple transactions in common stock on July 28, 2026.

Isaac Ro, a Director of Seer, Inc., reported multiple transactions in common stock on July 28, 2026.

Reshma P. Shetty, See remarks, a Director and 10% owner of Ginkgo Bioworks Holdings, Inc., reported multiple transactions in common stock on July 28, 2026.

Sean P Downes, Executive Chairman and a Director of Universal Insurance Holdings, Inc., reported a transaction in 23,610 shares of common stock on July 28, 2026.

Renah Persofsky, a Director of Tilray Brands, Inc., reported multiple transactions in common stock on July 29, 2026.

Thomas P. Looney, a Director of Tilray Brands, Inc., reported multiple transactions in common stock on July 29, 2026.

Jason R Kelly, See remarks and a Director of Ginkgo Bioworks Holdings, Inc., reported multiple transactions in common stock on July 28, 2026.

Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 14,000 shares of common stock on July 30, 2026 for $79.88 per share.

Johann Michael Herhalt, a Director of Tilray Brands, Inc., reported multiple transactions in common stock on July 29, 2026.

Steven Michael Cohen, a Director of Tilray Brands, Inc., reported multiple transactions in common stock on July 29, 2026.

David F Clanachan, a Director of Tilray Brands, Inc., reported multiple transactions in common stock on July 29, 2026.

David G. Hopkinson, a Director of Tilray Brands, Inc., reported multiple transactions in common stock on July 29, 2026.